The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 48.50
High: 49.00
Low: 48.50
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

15 Feb 2016 07:00

RNS Number : 9846O
Cambridge Cognition Holdings PLC
15 February 2016
 

15th February 2016

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Directorate Change

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets computerised neuropsychological tests including those enabling the early detection of dementia, announces the appointment of Steven Powell as Chief Executive Officer ('CEO'). This confirms the role he accepted in July 2015 when the then CEO, Nick Kerton, took an extended leave of absence from the Company due to a serious medical condition.

 

With over 25 years of operational and investment experience in the pharmaceutical and life sciences sector, Steven joined the Company as Head of European Operations in 2014. In this position, he was heavily involved in the development and implementation of the current product strategy, which is now starting to establish the Company as the leading provider of point of care cognitive assessments for dementia. Since his appointment to the board as COO and Interim CEO in July 2015, he has driven that strategy forward successfully. As a result, the transition from COO to CEO has been a natural one under the circumstances.

 

Nick Kerton will remain as a Non-Executive Director continuing to support the Company with his extensive technical and market knowledge.

 

Non-Executive Chairman at Cambridge Cognition, Michael Lewis commented: "We would like to thank Nick for his significant contribution to the development of Cambridge Cognition and we are delighted that Steven has accepted the permanent role of CEO to continue the excellent work that he has been doing since July last year. I am sure that he will continue to develop our management team, evolve the strategy and take the business on to the next level."

 

Steven Powell, CEO of Cambridge Cognition, commenting on his new role: "I am delighted that I have the confidence of the board to lead the Company to the next phase of growth by implementing the plans that we have been formulating over the past year."  

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Steven Powell, Chief Operating Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Lianne Cawthorne

Mob: 07584 391 303

Paul McManus

Mob: 07980 541 893

 

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAMMGMZVZFGVZM
Date   Source Headline
27th Feb 20184:25 pmRNSHolding(s) in Company
10th Jan 20187:00 amRNSTrading Update and Notice of Results
5th Dec 20178:55 amRNSHolding(s) in Company
28th Nov 20177:00 amRNSWearable technology demonstrates high compliance
2nd Nov 20177:00 amRNSGrant of Options
10th Oct 201711:00 amRNSHolding(s) in Company
10th Oct 201710:58 amRNSHolding(s) in Company
6th Oct 20177:00 amRNSIssue of Equity
21st Sep 20177:00 amRNSHalf-year Report
12th Sep 20177:00 amRNSAward of Funding
31st Aug 20177:00 amRNSNotice of Results
12th Jun 20179:56 amRNSHolding(s) in Company
8th Jun 20177:00 amRNSDirector/PDMR Shareholding
7th Jun 20177:00 amRNSSpeech recognition for clinical trials
25th May 20172:22 pmRNSResult of AGM & Board Change
24th May 20174:27 pmRNSHolding(s) in Company
22nd May 20177:00 amRNSIssue of Equity
11th May 20171:07 pmRNSHolding(s) in Company
10th May 20177:00 amRNSGrant of Options
2nd May 20177:00 amRNSPosting of Annual Report & Notice of AGM
30th Mar 20177:00 amRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSAnnual Financial Report
16th Mar 20177:00 amRNSCANTAB used in EBBINGHAUS cognitive function trial
7th Mar 20177:00 amRNSLaunch of web-based testing for virtual research
24th Feb 20177:00 amRNSPartnership With Takeda For Wearables
23rd Feb 20177:00 amRNSNotice of Results
20th Feb 20177:00 amRNSAppointment of Joint Broker
25th Jan 20177:00 amRNSUS regulatory clearance for CANTAB Mobile
4th Nov 20167:00 amRNSGrant of Options
13th Oct 20167:00 amRNSContract
29th Sep 20167:00 amRNSContract Win
22nd Sep 20167:00 amRNSHalf Yearly Report
20th Sep 20167:00 amRNSContract signed
25th Aug 20167:00 amRNSNotice of Results
18th Aug 201610:27 amRNSHolding(s) in Company
16th Aug 20167:00 amRNSCognition Kit Feasibility Study
20th Jul 20167:00 amRNSContract Win
24th Jun 201612:33 pmRNSResult of AGM
22nd Jun 20167:00 amRNSDistribution Agreement with MANUS Neurodynamica
2nd Jun 20167:00 amRNSDistribution Agreement with AnthroTronix
25th May 20162:00 pmRNSNotice of AGM & Posting of Annual Report
6th May 20167:00 amRNSDirector Dealing
5th May 20167:00 amRNSCANTAB Mobile - submission for FDA clearance
3rd May 20163:06 pmRNSHolding(s) in Company
25th Apr 20162:00 pmRNSDirector Dealing
25th Apr 20167:01 amRNSPlacing to raise £1.25m
25th Apr 20167:00 amRNSFinal Results
11th Apr 20167:00 amRNSCANTAB Recruit release
4th Apr 20167:00 amRNSPresentation of Prototype Wearable
30th Mar 20164:06 pmRNSAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.